Table 3.
Univariate analysis and multivariate analysis of the prognostic factors on OS in patients with LS-SCLC and ES-SCLC
| Factors | LS-SCLC | ES-SCLC | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||||
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||||
|
|
|
|
|
|||||||||||
| MST (m) | 2-y OS (%) | 3-y OS (%) | P | HR | 95% CI | P | MST (m) | 2-y OS (%) | 3-y OS (%) | P | HR | 95% CI | P | |
| Gender | ||||||||||||||
| Male | 21.0 | 42.1 | 26.3 | 13.0 | 24.3 | 11.2 | ||||||||
| Female | 33.9 | 52.6 | 43.1 | 0.467 | 17.0 | 31.8 | 0.0 | 0.068 | ||||||
| Age (years) | ||||||||||||||
| 65-70 | 27.6 | 54.0 | 32.8 | 12.0 | 26.0 | 13.2 | ||||||||
| ≥ 70 | 19.0 | 37.7 | 26.6 | 0.268 | 14.0 | 25.3 | 10.9 | 0.941 | ||||||
| KPS | ||||||||||||||
| ≥ 80 | 20.7 | 42.5 | 23.7 | 13.0 | 23.7 | 10.2 | ||||||||
| < 80 | 24.0 | 50.0 | 30.6 | 0.816 | 14.0 | 26.3 | 15.4 | 0.361 | ||||||
| Wight loss | ||||||||||||||
| < 5% | 29.0 | 50.0 | 28.8 | 14.0 | 29.4 | 15.1 | 0.319- | |||||||
| ≥ 5% | 22.0 | 43.5 | 23.8 | 0.680 | 12.0 | 6.2 | 0.0 | 0.043 | 0.576 | 1.038 | 0.067 | |||
| Smoking | ||||||||||||||
| Yes | 21.0 | 38.3 | 22.3 | 12.0 | 25.7 | 11.6 | ||||||||
| No | 22.8 | 45.9 | 33.1 | 0.593 | 13.4 | 25.5 | 19.8 | 0.888 | ||||||
| Cycle of ChT | ||||||||||||||
| < 4 | 12.0 | 18.8 | 9.4 | 0.184- | 9.8 | 3.7 | 0.0 | 0.315- | ||||||
| ≥ 4 | 27.6 | 55.8 | 40.0 | < 0.001 | 0.348 | 0.658 | 0.001 | 16.0 | 33.6 | 17.3 | 0.003 | 0.529 | 0.889 | 0.016 |
| Pleural effuion | ||||||||||||||
| Yes | 20.7 | 33.3 | 0.0 | 11.7 | 29.6 | 8.6 | ||||||||
| No | 22.0 | 45.3 | 30.3 | 0.718 | 14.0 | 24.6 | 12.7 | 0.286 | ||||||
| Obstructive | ||||||||||||||
| Pneuontise | ||||||||||||||
| Yes | 17.7 | 43.7 | 29.7 | 13.0 | 24.1 | 11.0 | ||||||||
| No | 22.8 | 44.4 | 30.4 | 0.896 | 16.0 | 27.8 | 9.7 | 0.399 | ||||||
| Treatment 1 | ||||||||||||||
| TRT+ChT | 24.0 | 43.4 | 25.7 | 17.0 | 24.4 | 10.5 | 0.840- | |||||||
| ChT alone | 17.3 | 48.4 | 26.3 | 0.577 | 9.8 | 11.9 | 5.9 | 0.035 | 1.380 | 2.268 | 0.204 | |||
| Treatment 2 | ||||||||||||||
| S+ChT±TRT | 27.0 | 53.7 | 42.3 | 0.627- | ||||||||||
| ChT±TRT | 19.0 | 40.9 | 28.0 | 0.023 | 0.512 | 2.724 | 0.474 | |||||||
| NSE (ng/mL) | ||||||||||||||
| ≥ 17 | 21.0 | 43.3 | 24.7 | 0.231- | 12.3 | 22.8 | 11.9 | |||||||
| < 17 | 29.0 | 59.2 | 39.4 | 0.031 | 0.447 | 0.865 | 0.017 | 13.4 | 23.1 | 7.7 | 0.838 | |||
| CEA (ng/mL) | ||||||||||||||
| ≥ 3.4 | 22.0 | 39.2 | 26.9 | 14.0 | 26.5 | 12.6 | ||||||||
| < 3.4 | 29.0 | 57.6 | 20.4 | 0.211 | 13.0 | 23.0 | 5.7 | 0.397 | ||||||
OS, overall survival; LS-SCLC, limited-stage small cell lung cancer; ES-SCLC, extensive-stage small cell lung cancer; KPS, Karnofsky performance status; ChT, chemotherapy; TRT, thoracic radiation therapy; S, surgery; NSE, neuron-specific enolase; CEA, carcinoembryonic antigen.